Revenue segments as reported by the company.

Life Sciences Solutions

Analytical Instruments

Specialty Diagnostics

Laboratory Products and Services

Eliminations

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Amortization of acquisition-related intangible assets

Research and development

Restructuring and other costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Thermo Fisher Scientific

Life Technologies was a biotech company founded in November 2008 through a US$6.7 billion merger of Invitrogen Corporation and Applied Biosystems Inc. The joint sales of the combined companies were about $3.5 billion; they had about 9,500 employees, and owned more than 3,600 licenses and patents.

Life Technologies

Thermo Fisher Scientific, Inc. engages in the provision of analytical instruments, equipment, reagents and consumables, software, and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. The Life Sciences Solutions segment is composed of a portfolio of reagents, instruments, and consumables used in biological and medical research, discovery and production of new drugs and vaccines, as well as diagnosis of infection and disease. The Analytical Instruments segment offers instruments, consumables, software, and services that are used for a range of applications in the laboratory, on the production line, and in the field. The Specialty Diagnostics segment provides diagnostic test kits, reagents, culture media, instruments, and associated products used to increase the speed and accuracy of diagnoses. The Laboratory Products and Services segment is involved in providing everything needed for the laboratory, including a combination of self-manufactured and sourced products for customers in research, academic, government, industrial, and healthcare settings. The company was founded on October 11, 1960 and is headquartered in Waltham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Thermo Fisher excels in 2022, eyes growth amid challenges

Thermo Fisher Scientific delivered exceptional 2022 results with strong Q4 performance and robust full-year revenue. Growth strategy and segment strengths position the company well for continued success in 2023.
Challenges such as normalization of growth, margin influences, and market dynamics require strategic management. Opportunities in high-growth markets and next-gen technologies offer avenues for further expansion and value creation.
Maintaining a focus on innovation, sustainability, and operational efficiency will be key to navigating challenges and capitalizing on growth opportunities in 2023.
Overall, Thermo Fisher Scientific's solid financial performance, strategic focus, and market positioning set a positive trajectory for continued success and value creation in the coming year.

Thermo Fisher excels in Q1 despite COVID challenges, eyes growth

Thermo Fisher Scientific's Q1 2023 showcased resilience amid challenges, driven by innovation and strategic initiatives. While facing short-term headwinds, the company remains well-positioned for long-term growth through market opportunities and operational strengths.

Thermo Fisher faces market challenges, focuses on cost management and acquisitions

Thermo Fisher Scientific navigated a challenging macroeconomic environment in Q2 2023, with varied performance across end markets. The company is focused on managing costs, driving productivity, and pursuing strategic acquisitions to enhance capabilities. Despite challenges, Thermo Fisher remains committed to ESG priorities and market outperformance.

Thermo Fisher reports solid Q3 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q3 performance was solid, with revenue growth and strategic acquisitions driving market position strengthening.
While facing challenges like revenue impact in Q4 and customer caution, the company remains optimistic about industry outlook and growth opportunities.
The company's focus on innovation, ESG priorities, and operational efficiency positions it well for future growth and success.
Management's insights into 2024 outlook indicate a balanced approach to growth through strategic investments and operational improvements.

Thermo Fisher posts solid earnings, eyes growth amid market challenges

Thermo Fisher Scientific delivered strong financial performance in Q4 2023 and full-year 2023, driven by innovation and customer focus.
While facing challenges in certain segments and markets, the company remains optimistic about growth opportunities and market outpacing.
Strategic acquisitions, focus on sustainability, and operational excellence position Thermo Fisher for continued success in 2024 and beyond.
Guidance for 2024 indicates a focus on organic growth, stable segment margins, and a commitment to long-term market outperformance.

Thermo Fisher reports strong Q1 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q1 2024 earnings call highlighted strong financial performance driven by a proven growth strategy and disciplined capital deployment. While facing challenges in certain end markets and regulatory uncertainties, the company remains optimistic about future growth opportunities. Key strengths include innovation, strategic partnerships, and a focus on corporate social responsibility.

Thermo Fisher excels in Q2, raises 2024 guidance amid market challenges

Thermo Fisher Scientific's Q2 performance reflects resilience and strategic focus amidst market challenges. The company's emphasis on innovation, operational efficiency, and customer relationships positions it well for sustained growth. With a positive outlook for 2024 and a commitment to long-term success, Thermo Fisher remains a strong player in the industry.

Thermo Fisher excels in Q3 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q3 2024 earnings call showcased strong financial performance, strategic innovations, and growth opportunities.
While facing challenges in certain market segments, the company's focus on innovation, partnerships, and financial strength positions it well for future growth.
With raised EPS guidance and revenue expectations, Thermo Fisher is poised for continued success through market expansion and strategic initiatives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Best Buy

Nu Skin Enterprises

Parker-Hannifin

TTEC Holdings

Honing in on stocks with a history of dividend growth leads to a healthy portfolio, with greater scope of capital appreciation as opposed to simple dividend-paying stocks or those with high yields.

5 Top Dividend Growth Stocks to Buy on the Cheap

As of late, it has definitely been a great time to be an investor in Thermo Fisher Scientific (TMO).

Thermo Fisher's (TMO) Shares March Higher, Can It Continue?

Activision Blizzard

eBay

Take-Two Interactive Software

Williams-Sonoma

Growth names have been at the forefront of this new COVID world, and have kept society not only afloat, but growing and transitioning to this new normal. Nobody knows exactly what the future will hold, but our AI algorithms have identified standout growth stocks via our rating system.

Top Growth Stocks For November

IDEXX Laboratories

STERIS

3 Best Buys from the Prospering Medical Instruments Industry

BeiGene

BioNTech SE

Calliditas Therapeutics AB

I-Mab

Merck

Pfizer

Innoforce, a Hangzhou company, formed a JV with Thermo Fisher Scientific to build a large biologics and steriles drug development and manufacturing facility in the Hangzhou Airport Economic Demonstration Area. Decheng Capital had good reason to be pleased when Merck paid $2.75 billion to acquire VelosBio, a company formed in 2017 to develop ROR1 ADCs for cancer.

Week In Review: RemeGen, A Yantai Biologics Company, Completes $515 Million Hong Kong IPO

Carrier Global

FedEx

New Linde PLC

Pfizer Inc.'s (NYSE: PFE) coronavirus vaccine candidate may have turned in strong efficacy results, but the logistics it requires could impact the vaccine's eventual uptake.  Opportunity In Adversity: The mRNA vaccine jointly developed by Pfizer and BioNTech SE – ADR (NASDAQ: BNTX) requires a storage temperature of negative 70 degrees Celsius.

Pfizer's COVID-19 Vaccine Requires Cold Chain Storage: 7 Stocks That Could Benefit

Fortive

Lam Research

Microchip Technology

Union Pacific

The Board of Directors of Union Pacific has declared a quarterly dividend of 97 cents per share on the company's common stock, payable December 30, 2020, to shareholders of record November 30, 2020. Union Pacific has paid dividends on its common stock for 121 consecutive years.

Daily Dividend Report: Union Pacific, Lam Research, Thermo Fisher Scientific, Microchip Technology, Fortive

WALTHAM, Mass. and SHANGHAI, Nov. 6, 2020 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, and Innoforce, a bioinnovation-enabling company, today announced they have signed a joint venture agreement to establish a new pharma services facility...

Thermo Fisher Scientific and Innoforce Partner to Establish Biologics and Steriles Drug Manufacturing Facility in China

WALTHAM, Mass., Nov. 5, 2020 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its board of directors declared a quarterly cash dividend of $0.22 per share. The dividend will be paid on January 15, 2021, to shareholders of...

Thermo Fisher Scientific Declares Quarterly Dividend and Authorizes $2.5 Billion of Share Repurchases

Thermo Fisher (TMO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Thermo Fisher (TMO) Hits 52-Week High, Can the Run Continue?

SAN JOSE, Calif., Nov. 4, 2020 /PRNewswire/ -- Thermo Fisher Scientific, the world leader in serving science, and the Biopharmaceutical Analysis Training Laboratory (BATL) at Northeastern University, have entered into a collaborative agreement in a bid to advance analytical capabilities...

Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

Apple

NIKE

The most basic principle of stock market investing is buying a security at a lower cost than the price at which you expect to be able to sell it for in the future.

3 Stocks That Gurus Agree Deserve Their Sky-High Valuations

Advanced Micro Devices

Cognizant Technology Solutions

Danaher

QUALCOMM

Rockwell Automation

Virgin Galactic

The 2020s will see machine data become intelligence, intelligence become automation, and automation spread from factories to cities and your wrist. The post 7 5G Stocks to Buy for the Future of the Machine Internet appeared first on InvestorPlace.

7 5G Stocks to Buy for the Future of the Machine Internet

West Pharmaceutical Services

While vaccine makers hog the headlines, these equipment providers are critical to the global supply chain.

These 2 Under-the-Radar Stocks Could Be Key to Coronavirus Vaccine Distribution

AutoZone

PC Connection

Evergy Inc

McDonald's

After experiencing its worst quarter in history, U.S. GDP grew by 33.1% vs the 32% estimate- its fastest pace ever. However, as COVID cases continue surging without any stimulus in sight, markets are refusing to rally.

Top Stocks To Buy Today As Markets Marginally Recover Despite Positive GDP News

Covid-19 brought $2 billion in revenue to Thermo Fisher during the third quarter, and the company will put it to work for the next decade of biotech drug discovery. The post Thermo Fisher is More Than a Big Covid Winner appeared first on InvestorPlace.

Thermo Fisher is More Than a Big Covid Winner

WALTHAM, Mass., Oct. 27, 2020 /PRNewswire/ -- A newly expanded Direct-to-Patient service offering supports decentralized clinical trials to minimize clinical trial length and costs while maximizing patient enrollment and participation rates. The comprehensive offering now includes...

Thermo Fisher Scientific Expands Direct-to-Patient Clinical Trials Service Offerings

Revenue related to the coronavirus enabled Thermo Fisher Scientific Inc. (NYSE:TMO) to post huge sales and earnings gains in the third quarter. The Waltham, Massachusetts-based provider of diagnostic test kits, laboratory hardware and supplies recorded revenue of more than $8.5 billion from July through September, a 35% increase over the same period a year earlier.

Thermo Fisher's 3rd Quarter Boosted by Coronavirus Sales

Thermo Fisher Scientific Inc. (TMO) CEO Marc Casper on Q3 2020 Results - Earnings Call Transcript

Abbott Labs

Tesla

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

Thermo Fisher (TMO) posted a big beat this morning, while Verizon (VZ) and Abbott (ABT) topped expectations more mildly.

Verizon (VZ), Abbott (ABT), Thermo Fisher (TMO) Report Q3; Tesla (TSLA) After the Bell

Significant COVID-19 led business expansions, as well as Thermo Fisher's (TMO) base business growth contribute to a stunning Q3 performance.

Thermo Fisher (TMO) Q3 Earnings Beat on Life Sciences Sales

Thermo Fisher Scientific Inc. (NYSE: TMO) published its earnings report for the fiscal third quarter on Wednesday that topped analysts' estimates for earnings and revenue. Thermo Fisher jumped about 2.3% in premarket trading on Wednesday.

Thermo Fisher's adjusted per-share earnings jump 91% in the third quarter

Thermo Fisher earnings rose 91% vs. a year earlier, the best in years.

Thermo Fisher Earnings Growth Is Best In Years, Crushing Views

Shares of Thermo Fisher Scientific Inc. rose 2.3% in premarket trading Wednesday, after the life sciences and laboratory products company reported third-quarter profit and revenue that were well above expectations. Net income grew to $1.93 billion, or $4.84 a share, from $760 million, or $1.88 a share, in the year-ago period.

Thermo Fisher's stock jumps after big profit, revenue beats

WALTHAM, Mass., Oct. 21, 2020 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the third quarter ended September 26, 2020. Third Quarter 2020 Highlights Third quarter revenue increased 36% to $8.52...

News for Thermo Fisher Scientific Stock (TMO)